Drug Taste Masking and Taste Assessment Services and Technologies Markets, 2035 – Yahoo Finance
Dublin, July 28, 2022 (GLOBE NEWSWIRE) — The “Taste Masking and Taste Assessment Services and Technologies Market, Distribution by Type of Formulation, Type of Techniques, Scale of Operation and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035” report has been added to ResearchAndMarkets.com’s offering.
‘Taste Masking and Taste Assessment Services and Technologies Market, 2022-2035 report features an extensive study of the current market landscape, offering an informed opinion on the taste masking and taste assessment services and technologies. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this field.
The oral solid dosage (OSD) market is the largest segment in the pharmaceutical industry, anticipated to reach over USD 900 billion by 2027.
However, one of key concerns associated with this industry is that the active pharmaceutical ingredients (APIs) used in orally administered dosage forms inherently possess an unpleasant taste/odour. The existence of such taste in drug formulations is unappealing and has been shown to have a negative impact on patient compliance, particularly among the pediatric and geriatric patient population.
In fact, in an event hosted by Adare Pharma Solutions and International Flavors and Fragrances (IFF), it has been reported that 30% to 40% of the pediatric population refuses to take a solid or liquid medication and about 26% of the geriatric population reports difficulty in swallowing tablets and capsules. Given the fact that there are numerous taste receptors on the tongue, it is difficult to block the taste of such drugs pharmacologically.
Therefore, in order to overcome the bitter taste of drugs, numerous conventional and novel taste masking techniques are being employed by pharmaceutical players; these include addition of sweeteners, coating, microencapsulation and hot-melt extrusion. Studies have suggested that application of taste masking technologies in oral drugs can increase the patience compliance from 53% to 90%.
Various pharmaceutical companies are actively investing time, capital and resources to develop palatable, pleasant-taste drug formulations, as well as a variety of taste-masking and assessment procedures for the drug dosage forms meant for children and elderly patients.
However, the overall process of development and assessment of taste-masked formulations is associated with several challenges, including variation in taste and its intensity in different APIs due to varying chemistries, identifying globally acceptable tastes, developing flavor matching placebo formulations (for testing) ensuring compliance with stringent regulatory guidelines and good clinical practices (GCPs), clinical research costs, and managing product life cycle.
The aforementioned reasons have prompted the pharmaceutical companies to outsource the taste masking and taste assessment related operations to third party service providers with expertise in this area.
Presently, 50 companies claim to offer services for taste-masking and taste-assessment, development and commercialization of taste masked formulations in compliance with the regulatory guidelines. Service providers also assist in assessment of taste masking agents in order to develop technologies suitable for wide range of formulations with different APIs.
Over time, centralized agencies, including the US Food and Drug Administration (US FDA) and European Medicines Agency (EMA) have streamlined efforts related to assessing the palatability of taste-masked drugs.
Additionally, the last few years have witnessed several strategic alliances between the players in this domain for expansion of existing taste masking capabilities to ensure drug formulations’ palatability and commercial success.
Moreover, stakeholders are actively looking for patient-centric and age-appropriate dosage forms and novelexcipients. Given the ongoing efforts to enhance palatability of oral drug formulations, drug adherence and patient compliance, the taste-masking and taste assessment technologies and services market is likely to evolve at a steady pace in the next few years.
One of the key objectives of the report was to estimate the existing market size and future growth potential of the taste masking and taste assessment services and technologies market. We have provided informed estimates on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035.
Key Questions Answered
Who are the leading players engaged in providing taste masking and taste assessment services and technology platforms?
Which companies offer taste masking technologies for licensing?
What kind of partnership models are commonly adopted by industry stakeholders?
What is the relative competitiveness of different taste masking and taste assessment service providers based in different geographies?
How has the intellectual property landscape in this field evolved over the years?
How is the current and future opportunity, related to taste masking and taste assessment likely to be distributed across key market segments?
Key Topics Covered:
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Bitterness of Oral Drugs and Need for Taste Masking
3.3. Physiology of Taste Buds
3.4. Concept of Taste Masking
3.5. Introduction to Taste Assessment
4. TASTE MASKING AND TASTE ASSESSMENT SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Taste Masking and Taste Assessment Service Providers
4.3. Taste Masking and Taste Assessment Services: Overall Market Landscape
5. TASTE MASKING AND TASTE ASSESSMENT TECHNOLOGY PROVIDERS: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Taste Masking and Taste Assessment Technologies: Overall Market Landscape
5.2.1. Analysis by Type of Service(s) Offered
5.2.2. Analysis by Technique(s) Used
5.2.3. Analysis by Type of Formulation
5.2.4. Analysis by End users
5.3. Taste Masking and Taste Assessment Technology Providers
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
5.3.4. Analysis by Year of Establishment and Location of Headquarters
5.3.5. Analysis by Company Size and Location of Headquarters
5.3.6. Leading Players: Analysis by Number of Technologies
6. TASTE MASKING AND TASTE ASSESSMENT SERVICE PROVIDERS: COMPANY PROFILES
6.1. Chapter Overview
6.2. AbbVie
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Taste Masking and Taste Assessment Service Portfolio
6.2.4. Recent Developments and Future Outlook
6.3. Catalent
6.4. Fertin Pharma
6.5. Lonza
6.6. NextPharma
6.7. Patheon
6.8. Quotient Sciences
6.9. Senopsys
7. TASTE MASKING AND TASTE ASSESSMENT TECHNOLOGY PROVIDERS: COMPANY PROFILES
7.1. Chapter Overview
7.2. Adare Pharma Solutions
7.2.1. Company Overview
7.2.2. Taste Masking and Taste Assessment Technology Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. Colorcon
7.4. Lupin
7.5. Mayne Pharma
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology and Key Parameters
8.3. Taste Masking and Taste Assessment Service Providers
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Taste Masking and Taste Assessment: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Collaboration
9.3.3. Analysis by Year and Type of Collaboration
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Type of Partner and Year of Partnership
9.3.6. Analysis by Type of Service(s) Offered
9.3.7. Analysis by Scale of Operation
9.3.8. Analysis by Type of Formulation
9.3.9. Regional Analysis
9.3.10. Most Active Players based on Number of Partnerships
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Patent Benchmarking Analysis
10.4. Patent Valuation Analysis
10.5. Leading Patents based on Number of Citations
11. CASE STUDY: EXCIPIENTS USED IN PHARMACEUTICAL TASTE MASKING
11.1. Chapter Overview
11.2. Types of Pharmaceutical Excipients
11.3. Pharmaceutical Taste Masking Excipients: Overall Market Landscape
11.4. Pharmaceutical Taste Masking Excipient Providers: Market Landscape
12. MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3 Taste Masking and Taste Assessment Services Market, 2022-2035
12.4. Taste Masking and Taste Assessment Services Market, 2022-2035: Distribution by Scale of Operation
12.5. Taste Masking and Taste Assessment Services Market, 2022-2035: Distribution by Geographical Regions
13. CONCLUDING REMARKS
14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Glatt Pharmaceutical Services
14.3 Senopsys
14.4. Adare Pharma Solutions
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Companies Mentioned
Aavis Pharmaceuticals
AbbVie
Adare Pharma Solutions
Allergan
Alpex Pharma
Aprecia Pharmaceuticals
Aquestive Therapeutics (formerly known as MonoSol Rx)
Arcinova
Ash Stevens
ATHENA Pharmaceutiques
Aurigene
Avista Pharma Solutions
axapharm
Azelis Americas
Battelle
BioGeneration Ventures
Biohaven Pharmaceutical Holding Company
Bionpharma
Bridge Therapeutics
BroadOak Capital Partners
Cambrex
Capsugel
Catalent
Chiasma
CMIC Group
Coating Place
Colorcon
Commonwealth Scientific and Industrial Research Organisation
CordenPharma
CoreRx
CrystecPharma
Cybin
Cynapsus Therapeutics
Edenbridge Pharmaceuticals
Egalet
Emerald Health Pharmaceutical
ESSA Pharma
Ethicann Pharmaceuticals
Evotec
Farragut
Fertin Pharma
Fluid Pharma
Forbion
ForTe-bv (sunsidiary of ForTe IQ bv)
Frazier Healthcare Partners
Frontida BioPharm (acquired by Adare Pharma Solutions)
G&W Laboratories
GALENIX
GB Sciences
Glatt Pharmaceutical Services
Globela Pharma
Glycologic
GPT Pharma
Haisco Pharmaceutical
Halo Pharma
HARKE Pharma
HERMES PHARMA
Hovione
i2o Therapeutics
Ideal Cures
InnovaNutra
Innovation Pharmaceuticals
INPHARMASCI (acquired by ATHENA)
Jubilant Pharma
Kola Pharma
Korsch
Lonza
Losan Pharma
Lubrizol Life Science Health
Lupin
Lyne Laborataries
Mayne Pharma
Medis
Metrics Contract Services
Mikart
Mithra Pharmaceuticals
Mitsubishi Tanabe Pharma
Nanoform
Nautic Partners
Nextar
NextPharma
Novast
Nucleo Life Sciences (acquired by CoreRx)
Opertech Bio
Orbis Biosciences
Oxford Pharmascience
Particle Dynamics
Patheon
Paulaur
Pensatech Pharma
Pfizer
Pharmaceutical Manufacturing Research Services
Pharmaceutical Product Development
Pharmaterials
Phathom Pharmaceuticals
Phil
Philip Morris International
Piramal Pharma Solutions
ProCepT
Purdue University
Quay Pharma
Quotient Sciences
RedHill Biopharma
Research Corporation Technologies
Rubicon Research
Senopsys
SGS
Shire
SkyePharma
SPI Pharma
SRLPharma
Stabicon Life Sciences
Sunvij Drugs
TasteTech
Teva Pharmaceuticals
Therabel
Thermo Fisher Scientific
Thomas H. Lee Partners
University of Hertfordshire
UPM Pharmaceuticals
Vertex Pharmaceuticals
Vifor Pharma
Wellesta Holdings
Xedev
ZIM Laboratories
For more information about this report visit https://www.researchandmarkets.com/r/tqsx31
As the LGBTQ+ community learns more about the MPV public health emergency, the federal government is making access to treatment easier.
On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look for updates on its pipeline candidates, especially its lead candidate exa-cel.
A federal court ruling has dealt a blow to Bausch Health by appearing to clear the way for generic competition for the company’s drug Xifaxan. Bausch Health stock (ticker: BHC) plummeted more than 50% Thursday morning on the news, and trading of the shares was halted. In 2020, Bausch Health Ireland and Salix Pharmaceuticals sued Norwich Pharmaceuticals in 2020 for patent infringement, regarding Norwich’s plans to bring a generic version of Xifaxan to market before its patents had expired, according to a Bloomberg Law report.
Since the early days of the COVID-19 pandemic, experts have warned that the coronavirus's effects can last for weeks or months after its first symptoms fade. "Long COVID" is still poorly understood, and it remains a risk even as variants of the virus produce milder initial illness. In fact, long COVID can surface even if your infection was originally asymptomatic. These are some of the sure signs you've already had COVID, which may have turned into long COVID, according to Fauci. Read on to find
You pretty much know what to expect when you head to the pharmacy, whether it's to pick up a prescription or some much needed over-the-counter (OTC) relief. But what you don't expect is to end up with meds that are part of a major recall, potentially putting you or your loved ones in danger. Unfortunately, that's exactly what happened with one popular variety of medication sold at CVS, Rite Aid, and Walgreens, among other drugstores. Read on to find out what meds are now subject to an expanded r
Breast explant surgery inquiries have been on the rise. These women share why.
The physicians from Ukraine are in Akron through Global Ties Akron and the Congressional Office for International Leadership.
In retirement, you’re going to face many risks, such as outliving your money, investment losses, unexpected health expenses, unforeseen needs of family members, and maybe even retirement benefit cuts. How important are those risks and do retirees properly perceive these risks when making their spending and investment decisions? In his research, Hou quantified the magnitude of the objective risks that retirees face as well as retirees’ subjective perceptions of the risks, and then compared the two.
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?
Is Pfizer stock a sell after Wall Street reduced its expectations for 2022 sales and profit? Is PFE stock a sell right now?
Dementia is a brain disorder that affects an estimated 55 million people worldwide according to the World Health Organization. The condition is becoming more common and while age is a leading risk factor, people under 65 can also have dementia, which causes memory loss, mood changes, getting lost in familiar places and more. Being aware of other risk factors like lack of sleep, poor diet, social isolation and not enough exercise can make a difference, but so does knowing your blood type, accordi
Bausch Health Companies Inc. (NYSE/TSX: BHC), and its gastroenterology business Salix Pharmaceuticals, today announced the U.S. District Court of Delaware issued an Oral Order in the matter of Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc. regarding the infringement and validity of certain U.S. Patents protecting the composition and use of XIFAXAN® (rifaximin) 550 mg tablets for the treatment of irritable bowel syndrome with diarrhea (IBS-D) and reduction in risk of overt hep
No, your body isn’t gaslighting you.
Strong quarterly sales of Pfizer’s Covid-19 products helped offset mixed results from other products, and the drugmaker sees full-year revenue gains being offset by unfavorable currency effects.
Data suggests there's a certain number of minutes you should aim for to improve your cardiovascular health. Here's how you can sneak them in.
Did you know that some of your daily habits could be sabotaging your quest to live a clean lifestyle? While we all know the major bad behaviors to avoid like smoking, having too much excess fat and not getting 150 minutes of exercise per week, as the Centers for Disease Control and Prevention recommends, there's so many other unhealthy habits that are harmful and just gross. Eat This, Not That! Health spoke with several experts who share the unhealthiest bad habits to stop now. Read on—and to en
The U.S. House of Representatives late Tuesday passed the Medical Marijuana and Cannabidiol Research Expansion Act (H.R. 8454) by a vote of 325 to 95. Introduced on July 21 by Reps. Earl Blumenauer – a Democrat from Oregon, and Andy Harris, a Republican from Maryland – the measure resembles Senate Bill 253 passed by the Senate in April, according to an article by the National Organization for the Repeal of Marijuana Laws (NORML). Harris, who is not in favor of cannabis legalization, supports mor
CDC issues health advisory about bacteria that causes rare serious disease
Reuters reported that World Health Organization's (WHO) scientist advisors on monkeypox say the window is closing to stop its spread. The cases are currently doubling every two weeks, raising concerns that the outbreak will take several months to peak. "The alarm bell was going off (in Africa), but we kept hitting the snooze button. Now it's time to wake up and do something about it," said Anne Rimoin, an epidemiology professor at the University of California. "An infection anywhere is potential
An apparent effort by Vice President Kamala Harris to accommodate the visually impaired and the LGBTQ community at an event commemorating the anniversary of the Americans with Disabilities Act (ADA) was widely mocked by Republicans and conservatives on Tuesday.